Abeona Signs Exclusive License Agreement with Regenxbio to Develop and Commercialize NAV AAV9 vector
Shots:
- Regenxbio to get $100M as total deal value plus $20M upfront ($10M paid on signing- $10M with 12 mos.) in addition to $60M milestone payment on sales
- Abeona to hold exclusive WW rights of Regenxbio’s NAV AAV9 vector- to develop gene therapies for the treatment of MPS IIIA- MPS IIIB- CLN1 and CLN3
- Regenxbio’s NAV AAV9 vector is based on its NAV Technology Platform indicated for the treatment of systemic and CNS manifestations
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
